Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
The risks that can come from buying these assets are precisely why we started StockStory — to isolate the long-term winners from the losers so you can invest with confidence. On that note, here are three growth stocks whose momentum may slow and some other opportunities you should look into instead.
Vital Farms (VITL)
One-Year Revenue Growth: +16.4%
With an emphasis on ethically produced products, Vital Farms (NASDAQ: VITL) specializes in pasture-raised eggs and butter.
Why Are We Bearish on VITL?
- Costs have risen faster than its revenue over the last year, causing its operating margin to decline by 10.3 percentage points
- Incremental sales over the last three years were much less profitable as its earnings per share fell by 17.2% annually while its revenue grew
- Capital intensity has ramped up over the last year as its free cash flow margin decreased by 13.6 percentage points
Vital Farms’s stock price of $10.79 implies a valuation ratio of 14.4x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including VITL in your portfolio.
First Financial Bancorp (FFBC)
One-Year Revenue Growth: +15.8%
Tracing its roots back to 1863 during the Civil War era, First Financial Bancorp (NASDAQ: FFBC) is a bank holding company that provides commercial banking, lending, deposit services, and wealth management to individuals and businesses.
Why Are We Wary of FFBC?
- Muted 9.7% annual revenue growth over the last five years shows its demand lagged behind its banking peers
- Net interest income trends were unexciting over the last five years as its 9.3% annual growth was below the typical banking firm
- Earnings growth underperformed the sector average over the last five years as its EPS grew by just 9% annually
At $32.82 per share, First Financial Bancorp trades at 1.1x forward P/B. If you’re considering FFBC for your portfolio, see our FREE research report to learn more.
Phibro Animal Health (PAHC)
One-Year Revenue Growth: +17.1%
With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ: PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.
Why Does PAHC Fall Short?
- Revenue base of $1.52 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Estimated sales growth of 3.6% for the next 12 months implies demand will slow from its two-year trend
- Low free cash flow margin of 0.9% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
Phibro Animal Health is trading at $38.40 per share, or 10.4x forward P/E. To fully understand why you should be careful with PAHC, check out our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
